Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood

with No hi ha comentaris
  • Bailón, L., Puertas, M., García-Guerrero, M., Moraes-Cardoso, I., Aparicio, E., Alarcón-Soto, Y.,…Blanco, J., Olvera, A.,  Mothe, B., Grp, D. S. (2024). Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae530 (En premsa)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *